| Business Summary | | Inhale
Therapeutic
Systems,
Inc.
is
a
supplier
of
drug
delivery
solutions.
The
Company
is
creating
a
drug
delivery
system
to
deliver
a
wide
range
of
drugs,
including
peptides,
proteins,
nucleic
acids
and
other
molecules,
by
inhalation
to
the
deep
lung.
Inhale
Therapeutic
Systems
is
using
this
system
principally
to
enable
non-invasive
delivery
of
macromolecule
drugs
otherwise
administered
by
injection.
The
Company's
most
advanced
program,
which
is
sponsored
by
Pfizer
Inc.,
is
inhalable
insulin.
In
addition
to
its
insulin
program
with
Pfizer,
the
Company
has
development
collaborations
with
Biogen,
Inc.,
Aventis
Behring
L.L.C.
(formerly
Centeon
L.L.C.,
a
joint
venture
of
Hoechst
AG
and
Rhone-Poulenc
S.A.,
which
have
now
merged
to
form
Aventis
S.A.)
and
Eli
Lilly
&
Co.
The
Company
also
has
early
stage
feasibility
and
research
collaborations
with
several
other
companies,
and
has
tested
eight
drugs
in
clinical
trials. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Inhale
Therapeutic
Systems
is
creating
an
inhalation
drug
delivery
system
to
deliver
peptides,
proteins
and
other
macromolecule
drugs
into
the
deep
lung.
For
the
six
months
ended
6/30/01,
revenues
increased
27%
to
$30.9
million.
Net
loss
totaled
$186.8
million,
up
from
$44.6
million.
Revenues
reflect
the
expansion
of
the
Company's
collaborative
agreement
with
Pfizer,
Inc.
Higher
loss
reflects
a
$83.6
million
charge
for
in-process
research
and
development. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Robert Chess, 44 Chairman | $926K | $7.3M | Ajit Gill, 52 Pres,
CEO, Director | 1.1M | 7.9M | Brigid Makes, 45 CFO,
Assistant Sec., VP of Fin. and Admin. | 283K | -- | John Patton, Ph.D., 54 VP,
Research | 303K | -- | Stephen Hurst, 45 Sec.,
Gen. Counsel, VP | 271K | 3.4M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|